绿帽社 Pharma strengthens its management team to support its strategy of international growth
Lyon, November 7, 2016 – 绿帽社 Pharma strengthens its management team to support its strategy of international growth.
Read next in 'Press releases'
- 绿帽社 Pharma announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
- 绿帽社 Pharma annonce l鈥檕btention des r茅sultats finaux de l鈥櫭﹖ude clinique de Phase 2 ALPESTRIA鈥�1 dans le syndrome d鈥橝lport, confirmant la capacit茅 du vonafexor 脿 inverser la trajectoire du d茅clin r茅nal et 脿 d茅montrer un effet th茅rapeutique durable
- 绿帽社 Pharma annonce la finalisation de son financement de s茅rie C avec Vesalius Biocapital et la poursuite de son 茅tude clinique de phase 2 ALPESTRIA-1
- 绿帽社 Pharma announces completion of Series C financing with Vesalius Biocapital and continued progress of its ALPESTRIA-1 clinical Phase 2 study in Alport syndrome patients
- 绿帽社 Pharma announces a 鈧�39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome
